AU2018329628B2 - Pridopidine for treating drug induced dyskinesias - Google Patents

Pridopidine for treating drug induced dyskinesias Download PDF

Info

Publication number
AU2018329628B2
AU2018329628B2 AU2018329628A AU2018329628A AU2018329628B2 AU 2018329628 B2 AU2018329628 B2 AU 2018329628B2 AU 2018329628 A AU2018329628 A AU 2018329628A AU 2018329628 A AU2018329628 A AU 2018329628A AU 2018329628 B2 AU2018329628 B2 AU 2018329628B2
Authority
AU
Australia
Prior art keywords
pridopidine
subject
levodopa
day
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018329628A
Other languages
English (en)
Other versions
AU2018329628A1 (en
Inventor
Michal Geva
Michael Hayden
Aric ORBACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2018329628A1 publication Critical patent/AU2018329628A1/en
Application granted granted Critical
Publication of AU2018329628B2 publication Critical patent/AU2018329628B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018329628A 2017-09-08 2018-08-30 Pridopidine for treating drug induced dyskinesias Active AU2018329628B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US62/556,314 2017-09-08
US201862649184P 2018-03-28 2018-03-28
US62/649,184 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
AU2018329628A1 AU2018329628A1 (en) 2020-04-16
AU2018329628B2 true AU2018329628B2 (en) 2021-04-22

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018329628A Active AU2018329628B2 (en) 2017-09-08 2018-08-30 Pridopidine for treating drug induced dyskinesias

Country Status (10)

Country Link
US (2) US20190231768A1 (https=)
EP (1) EP3678664A1 (https=)
JP (1) JP2020533296A (https=)
CN (1) CN111343982A (https=)
AU (1) AU2018329628B2 (https=)
BR (1) BR112020004622A2 (https=)
CA (1) CA3075020C (https=)
IL (1) IL273044A (https=)
MX (1) MX383462B (https=)
WO (1) WO2019050775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
KR102906269B1 (ko) 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428822A2 (en) * 1999-12-22 2004-06-16 A. Carlsson Research AB 1-phenylpiperazine derivative as modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
WO2008155357A2 (en) * 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
JP6526695B6 (ja) 2014-03-10 2019-06-26 アプライド マテリアルズ インコーポレイテッドＡｐｐｌｉｅｄ Ｍａｔｅｒｉａｌｓ，Ｉｎｃｏｒｐｏｒａｔｅｄ 多重荷電粒子ビームリソグラフィのためのピクセルブレンディング
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) * 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428822A2 (en) * 1999-12-22 2004-06-16 A. Carlsson Research AB 1-phenylpiperazine derivative as modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PONTEN HENRIK et al.: "The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model", EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, vol. 698, no. 1-3, pages 278 - 285 *

Also Published As

Publication number Publication date
US20190350914A1 (en) 2019-11-21
AU2018329628A1 (en) 2020-04-16
IL273044A (en) 2020-04-30
US20190231768A1 (en) 2019-08-01
EP3678664A1 (en) 2020-07-15
JP2020533296A (ja) 2020-11-19
MX383462B (es) 2025-03-14
CA3075020C (en) 2021-12-07
BR112020004622A2 (pt) 2020-09-24
CN111343982A (zh) 2020-06-26
US11000519B2 (en) 2021-05-11
CA3075020A1 (en) 2019-03-14
WO2019050775A1 (en) 2019-03-14
MX2020002645A (es) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2018329628B2 (en) Pridopidine for treating drug induced dyskinesias
Pahwa et al. New antipsychotic medications in the last decade
Baldessarini et al. Pharmacotherapy of psychosis and mania
Tsai et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
CA2500662A1 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
MX2015003812A (es) Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2816595C (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2023523569A (ja) 神経学的および精神障害の治療方法
Monti The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder
US20200323823A1 (en) Methods for the treatment of depression
EP2288345A1 (en) Psycho-pharmaceuticals
JP2017519827A (ja) ブスピロン代謝産物の使用
US20200129455A1 (en) Composition and method for treating neurological disease
WO2020110128A1 (en) Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US20240197756A1 (en) Methods of treatment with neuroactive steroids
Deeks et al. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression
US12036213B2 (en) Pridopidine for treating drug induced dyskinesias
EP3941466B1 (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
HUP0101341A2 (hu) Új gyógyszer-kombinációk
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response patterns
HK40067920A (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
WO2012072665A1 (en) Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
HK1036592A (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)